The National Institute of Child Health and Human Development (NICHD) is conducting a Phase III multicenter, open-label, non-comparative trial (Protocol number: CCN008;""""""""A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom"""""""") to determine the contraceptive efficacy ofthe Woman's Condom (WC). A secondary objective of the trial is to assess the perfonnance of the WC in a subset of women by evaluating whether a biological marker of semen exposure (i.e., prostate-specific antigen (PSA)) is present in post""""""""coital vaginal fluid specimens. Detection of the semen biomarker in the vagina following the use of a female condom may be a more sensitive measure of female condom failure as a barrier than either pregnancy or infection. The Biomarker Substudy will be nested within the CCN008 trial. NICHD will enroll a subset of subjects (N=150) to collect vaginal swabs and the used female condoms for testing for PSA detection. Each of the 150 subjects is to provide three specimens (pre and post-coital swabs and the used condom) for each of four acts. Thus, an estimated 1,800 specimens will be tested for PSA.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code